A randomized comparison of a rivaroxaban-based strategy with an antiplatelet-based strategy following successful TAVR for the prevention of leaflet thickening and reduced leaflet motion as evaluated by four-dimensional, volume-rendered computed tomography (4DCT)

The GALILEO-4D trial is conducted as a substudy of the multicenter, open-label, randomized, event-driven, active-controlled GALILEO trial. Click here for more information about the GALILEO trial

The Principal Investigator is Professor Lars Søndergaard (Denmark) and co Principal Investigator is Doctor Ole De Backer (Denmark). 

The European Cardiovascular Research Institute (ECRI) acts as sponsor for the GALILEO 4D trial. ECRI is being supported by a scientific grant from Bayer.

The GALILEO 4D trial will be registered at shortly: